Teza Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Teza Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-4,138	Closed	-$227K	–	83
2025 Q2	$227K	Sell	4,138 -6,086	-60%	-$358K	0.17%	242
2025 Q1	$723K	Buy	+10,224	New	+$688K	0.33%	87
2024 Q4	–	Sell	-8,833	Closed	-$621K	–	527
2024 Q3	$621K	Buy	+8,833	New	+$738K	0.07%	332
2023 Q3	–	Sell	-4,430	Closed	-$384K	–	601
2023 Q2	$384K	Buy	4,430 +1,754	+66%	+$165K	0.06%	343
2023 Q1	$260K	Buy	+2,676	New	+$277K	0.06%	411
2022 Q4	–	Sell	-4,162	Closed	-$353K	–	585
2022 Q3	$353K	Buy	+4,162	New	+$371K	0.07%	377
2021 Q2	–	Sell	-6,716	Closed	-$507K	–	559
2021 Q1	$507K	Buy	6,716 +476	+8%	+$38.9K	0.1%	268
2020 Q4	$547K	Buy	+6,240	New	+$495K	0.31%	111
2020 Q3	–	Sell	-3,121	Closed	-$385K	–	391
2020 Q2	$385K	Buy	+3,121	New	+$310K	0.09%	338
2017 Q2	–	Sell	-8,545	Closed	-$750K	–	49
2017 Q1	$750K	Buy	+8,545	New	+$760K	0.22%	151

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Teza Capital Management's BMRN Position: Q3 2025 in Review

Teza Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2025, closing a stake of 4,138 shares — an estimated $227K sold.

Teza Capital Management first reported a position in BMRN in Q1 2017 and held it in 10 quarters. The position peaked at $750K in Q1 2017. 576 funds tracked by Wall St. Rank hold BMRN as of Q3 2025.

Teza Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Teza Capital Management sold 4,138 BioMarin Pharmaceuticals shares in Q3 2025, an estimated $227K.
Teza Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and held it in 10 quarters.
Teza Capital Management's BioMarin Pharmaceuticals position peaked at $750K in Q1 2017.
576 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2025.

Based on Teza Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.